rna-lipoplex cancer vaccine bnt116
Generic: RNA-lipoplex Cancer Vaccine BNT116
rna-lipoplex cancer vaccine bnt116: 1 clinical trial tracked.
rna-lipoplex cancer vaccine bnt116 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about rna-lipoplex cancer vaccine bnt116, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Primary endpoint: Cohorts 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, EGFR and ALK/RET: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation Period
Interventionalopen320 targetStarted 2022-06Completion 2031-1145 sites · Australia, Germany, Hungary, Poland…BioNTech SE